International GLP-1 Pricing: Why Americans Pay 10× More
A month of Wegovy costs approximately $1,349 in the United States. The same drug, made by the same company, costs a fraction of that in Germany, the UK, Denmark, and Japan. In markets where generic semaglutide is emerging, prices drop below $100. Here's the global pricing landscape and the structural factors that create the disparity.
The international pricing gap for GLP-1 drugs is not a rounding error — it's a structural feature of how different healthcare systems negotiate drug prices. The United States is the only major market where pharmaceutical companies can set prices without government negotiation, and the result is striking. Novo Nordisk's 2024 revenue from Wegovy and Ozempic exceeded $26 billion, with the US accounting for the majority of that revenue despite not having the majority of patients.
Country-by-Country Price Comparison
| Country | Wegovy (approx. monthly) | Price Mechanism |
|---|---|---|
| United States | ~$1,349 | Manufacturer list price; PBM negotiations |
| Germany | ~$186–$250 | Federal reference pricing + AMNOG evaluation |
| United Kingdom | ~$220–$300 | NICE cost-effectiveness assessment |
| Denmark | ~$250–$350 | National negotiation |
| Japan | ~$200–$280 | NHI drug pricing formula |
| Canada | ~$300–$400 | PMPRB ceiling + provincial negotiation |
| India (emerging generics) | ~$40–$80 | Price controls + generic competition |
| China (generic pipeline) | ~$50–$100 (est.) | Patent expiry 2026; volume-based procurement |
Why the US Pays More
Three structural factors drive the disparity. First, Medicare was historically prohibited from negotiating drug prices directly with manufacturers (the Inflation Reduction Act of 2022 changed this for select drugs, but GLP-1s for obesity are not yet on the negotiation list). Second, the US allows direct-to-consumer advertising, which drives demand and gives manufacturers pricing power. Third, the pharmacy benefit manager (PBM) system creates opaque rebate structures where the list price diverges significantly from the net price — but the list price still determines out-of-pocket costs for many patients.
Novo Nordisk and Eli Lilly have responded to pricing pressure with direct-to-consumer programs (NovoCare, LillyDirect) that offer lower cash-pay prices, but these remain substantially higher than international prices.
The Generic Horizon
Semaglutide patents expire in China and India in 2026, making these the first major markets likely to see generic competition. Multiple manufacturers in both countries are developing semaglutide production capabilities. The US won't see generic semaglutide until at least 2031–2032 (see our patent cliff analysis for details).
International generics cannot be legally imported to the US, but their emergence will create global price pressure and may influence US pricing discussions — particularly as the BALANCE Model and state-level coverage mandates increase government payer exposure to GLP-1 costs.
The US pricing gap is not primarily about drug development costs (which are amortized globally) but about the absence of price negotiation mechanisms that exist in every other major market. Until generic competition arrives in 2031+, or until GLP-1s are added to Medicare direct negotiation lists, the structural pricing disparity will persist. Patients traveling internationally should be aware that personal importation of prescription drugs is not legal under most circumstances.
Sources
- Novo Nordisk. 2024 Annual Report: Revenue breakdown by geography.
- I-MAK. GLP-1 patent analysis and pricing study. 2025. i-mak.org
- Chemical & Engineering News. Looming GLP-1 patent expirations. December 2025. cen.acs.org
- NICE. Semaglutide for chronic weight management: Technology Appraisal Guidance.